Hebbar Sudarshan

SEC source: 0001968793-26-000007 · form4-09282026_080927.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2036-09-23

F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.

SEC source: 0001968793-26-000006 · form4-08212026_100852.xml · derivative · entry 2

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,486

Underlying: Common Stock · 124,486 shares

Expires 2031-06-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F3 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to June 25, 2031; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001968793-26-000006 · form4-08212026_100852.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,486

Underlying: Common Stock · 124,486 shares

Expires 2027-12-25

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

F2 · derivative.exercise_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

F2 · derivative.expiration_date: The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the warrant may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation, not to exceed 19.99%.

SEC source: 0001968793-26-000004 · form4-06292026_080607.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,025

F1 · kind: The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

SEC source: 0001415889-25-022549 · form4-08212025_120801.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,539

F1 · price: The weighted average purchase price for the transaction reported was $2.8194, and the range of prices were between $2.74 and $2.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-022159 · form4-08182025_120801.xml · nonDerivative · entry 2

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,976

F2 · price: The weighted average purchase price for the transaction reported was $2.7930, and the range of prices were between $2.70 and $2.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-022159 · form4-08182025_120801.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,584

F1 · price: The weighted average purchase price for the transaction reported was $2.585, and the range of prices were between $2.57 and $2.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-018310 · form4-06262025_100630.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,300

Underlying: Common Stock · 83,300 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-011359 · form4-04252025_080420.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2035-04-22

F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period.

SEC source: 0001968793-26-000002 · form4-04072026_090409.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,173

Underlying: Common Stock · 91,173 shares

Expires 2036-04-04

F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

SEC source: 0001415889-24-022501 · form4-08282024_110856.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2034-08-26

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024.

SEC source: 0001415889-24-011344 · form4-04232024_010443.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2034-03-27

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-23-054632 · doc4.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,000

F1 · price: The weighted average purchase price for the transaction reported was $2.7389, and the range of prices were between $2.645 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-23-030780 · doc4.xml · nonDerivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

F1 · price: The weighted average purchase price for the transaction reported was $2.6999, and the range of prices were between $2.69 and $2.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001209191-23-028551 · doc4.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,709

Underlying: Common Stock · 60,709 shares

Expires 2033-05-07

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 16

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,108

Underlying: Common Stock · 3,108 shares

Expires 2023-03-19

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F22 · price: Received in exchange for a stock option to acquire 107,928 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F19 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 15

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,381

Underlying: Common Stock · 7,381 shares

Expires 2023-03-19

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F21 · price: Received in exchange for a stock option to acquire 256,287 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F19 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 14

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,836

Underlying: Common Stock · 23,836 shares

Expires 2033-03-19

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F20 · price: Received in exchange for a stock option to acquire 827,673 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F19 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 13

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,352

Underlying: Common Stock · 6,352 shares

Expires 2032-08-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F18 · price: Received in exchange for a stock option to acquire 220,588 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 12

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,954

Underlying: Common Stock · 1,954 shares

Expires 2032-08-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F17 · price: Received in exchange for a stock option to acquire 67,873 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 11

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 838

Underlying: Common Stock · 838 shares

Expires 2032-08-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F16 · price: Received in exchange for a stock option to acquire 29,117 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 10

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,880

Underlying: Common Stock · 2,880 shares

Expires 2032-08-01

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F15 · price: Received in exchange for a stock option to acquire 100,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 9

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,774

Underlying: Common Stock · 9,774 shares

Expires 2031-06-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F13 · price: Received in exchange for a stock option to acquire 339,404 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 8

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,782

Underlying: Common Stock · 18,782 shares

Expires 2031-04-27

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F14 · price: Received in exchange for a stock option to acquire 652,174 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 7

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,774

Underlying: Common Stock · 9,774 shares

Expires 2031-04-27

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F13 · price: Received in exchange for a stock option to acquire 339,404 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F12 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 6

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,778

Underlying: Common Stock · 11,778 shares

Expires 2030-06-29

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F11 · price: Received in exchange for a stock option to acquire 408,982 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F10 · derivative.exercise_date: 25% of the shares subject to the option vested on January 1, 2021 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 5

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,968

Underlying: Common Stock · 24,968 shares

Expires 2030-06-29

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F9 · price: Received in exchange for a stock option to acquire 866,952 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F8 · derivative.exercise_date: 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 4

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,524

Underlying: Common Stock · 2,524 shares

Expires 2040-01-23

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F7 · price: Received in exchange for a stock option to acquire 87,658 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 3

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,640

Underlying: Common Stock · 8,640 shares

Expires 2029-04-24

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F5 · price: Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 2

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,777

Underlying: Common Stock · 22,777 shares

Expires 2028-08-01

F3 · price: Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020678 · doc4.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,761

Underlying: Common Stock · 11,761 shares

Expires 2026-02-10

F2 · price: Received in exchange for a stock option to acquire 408,402 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

F1 · derivative.exercise_date: Immediately exercisable.